International Heart Journal
Online ISSN : 1349-3299
Print ISSN : 1349-2365
ISSN-L : 1349-2365

This article has now been updated. Please use the final version.

Relevant Adverse Events and Drug Discontinuation of Sacubitril/Valsartan in Patients with Transthyretin Amyloid Cardiomyopathy - Insights from the REVIEW-HF Registry
Yukihiro Watanabe, Yoshiaki Kubota, Hiroshige Murata, Saori Uchiyama, Kuniya Asai, Takahito Nasu, Shunsuke Ishii, Nobuyuki Kagiyama, Keisuke Kida, Wataru Fujimoto, Atsushi Kikuchi, Takeshi Ijichi, Tatsuhiro Shibata, Koshiro Kanaoka, Shingo Matsumoto
Author information
JOURNAL FREE ACCESS Advance online publication

Article ID: 25-686

Details
Abstract

Data on the safety and tolerability of sacubitril/valsartan in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are limited.

The REVIEW-HF registry was a nationwide, multicenter, retrospective study that investigated the characteristics and outcomes of patients with heart failure who were newly prescribed sacubitril/valsartan in Japan. We evaluated adverse events (AEs) related to sacubitril/valsartan within 3 months after initiation, defined as hypotension, worsening kidney function, hyperkalemia, and angioedema. The rates of AEs and sacubitril/valsartan discontinuation were compared between patients with and without ATTR-CM.

Among the 995 patients enrolled, 17 were diagnosed with ATTR-CM. Patients with ATTR-CM had a significantly higher incidence of AEs (64.7% versus 21.7%, P < 0.001), which were all attributable to hypotension. The discontinuation rate of sacubitril/valsartan was also significantly higher in these patients (76.5% versus 21.7%, P < 0.001), with a median discontinuation time of 8 days (interquartile range, 7-16). In multivariable analysis, ATTR-CM remained significantly associated with a higher risk of AEs (adjusted odds ratio, 7.35; 95% confidence interval, 2.40-22.55; P < 0.001) and sacubitril/valsartan discontinuation (adjusted odds ratio, 8.05; 95% confidence interval, 2.47-26.20; P < 0.001).

In conclusion, patients with ATTR-CM had a significantly higher incidence of hypotension and more frequent discontinuation of sacubitril/valsartan compared with those without ATTR-CM. Although the number of patients with ATTR-CM in this study was limited and the findings should be interpreted with caution, careful monitoring may be warranted after the initiation of sacubitril/valsartan in this population.

Content from these authors
© 2026 by the International Heart Journal Association
feedback
Top